Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with
Stenotrophomonas maltophilia
bacteremia
characteristics
mortality
outcomes
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 May 2022
30 May 2022
Historique:
received:
26
04
2022
revised:
24
05
2022
accepted:
27
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
This study aimed to establish the clinical features, outcomes, and factors associated with mortality in patients with Stenotrophomonas maltophilia (S. maltophilia) septicemia. The characteristics and outcome data used in this retrospective study were collected from medical records at Songklanagarind Hospital. Risk factors for survival were analyzed using χ2-tests, Kaplan−Meier curves, and Cox regression. A total of 117 patients with S. maltophilia bacteremia were analyzed. The patients’ median age was 45 years, 77 (70%) were male, 105 (90%) had comorbidities, 112 (96%) had previously undergone carbapenem therapy, and over half of the patients were on invasive medical devices. Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone showed high susceptibility rates to S. maltophilia, with 93% and 88% susceptibility, respectively. Patients who received appropriate empirical antibiotic treatment had significantly reduced 14-day, 30-day, and in-hospital mortality rates than those who did not (p < 0.001). The days of hospital stay and costs for those who received appropriate and inappropriate empirical antimicrobial treatment were 21 and 34 days (p < 0.001) and 142,463 and 185,663 baht, respectively (p < 0.002). Our results suggest that an appropriate empirical antibiotic(s) is significantly associated with lower 30-day mortality in hospitalized patients with S. maltophilia septicemia.
Identifiants
pubmed: 35683471
pii: jcm11113085
doi: 10.3390/jcm11113085
pmc: PMC9181236
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Faculty of Medicine, Prince of Songkla University
ID : REC:58368144
Références
J Microbiol Immunol Infect. 2004 Dec;37(6):359-65
pubmed: 15599468
J Infect Dev Ctries. 2014 Aug 13;8(8):1000-5
pubmed: 25116665
Biomed Res Int. 2019 Dec 9;2019:4931501
pubmed: 31886220
PLoS One. 2012;7(5):e37375
pubmed: 22624022
J Hosp Infect. 2008 Oct;70(2):101-8
pubmed: 18621440
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114
pubmed: 34864936
Antimicrob Agents Chemother. 2000 Feb;44(2):287-93
pubmed: 10639352
J Korean Med Sci. 2013 Jan;28(1):62-6
pubmed: 23341713
Lancet Infect Dis. 2009 May;9(5):312-23
pubmed: 19393961
Antimicrob Agents Chemother. 2014;58(1):581-3
pubmed: 24126583
Medicine (Baltimore). 2002 May;81(3):228-39
pubmed: 11997719
Int J Hematol. 2013 Mar;97(3):414-20
pubmed: 23430671
J Antimicrob Chemother. 2000 Jan;45(1):115-7
pubmed: 10629022
Clin Infect Dis. 2000 Sep;31(3):705-11
pubmed: 11017819
Clin Infect Dis. 2000 Jan;30(1):195-7
pubmed: 10619754
J Microbiol Immunol Infect. 2014 Feb;47(1):28-35
pubmed: 23040236
Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):901-6
pubmed: 18483755
Clin Microbiol Infect. 2018 Aug;24(8):865-870
pubmed: 29221995
Antimicrob Agents Chemother. 1997 May;41(5):1140-2
pubmed: 9145884
J Infect. 2002 Jul;45(1):47-53
pubmed: 12217732
Medicine (Baltimore). 2016 Aug;95(31):e4375
pubmed: 27495046
Antimicrob Agents Chemother. 2014;58(1):176-82
pubmed: 24145530
Future Microbiol. 2009 Nov;4(9):1103-9
pubmed: 19895214
Scand J Infect Dis. 1994;26(2):163-70
pubmed: 8036472
Eur J Clin Microbiol Infect Dis. 2007 Jan;26(1):13-20
pubmed: 17200840
Infect Drug Resist. 2020 May 28;13:1559-1566
pubmed: 32547125
PLoS One. 2021 Jan 6;16(1):e0244673
pubmed: 33406110